Sfoglia per Autore
Investigating the inhibition mechanism and catalytic cycle of MbtI, the salicylate synthase from Mycobacterium tuberculosis
2020 M. Mori, S. Villa, A. Gelain, E.R.E. Pini, G. Stelitano, L.R. Chiarelli, T. Tuccinardi, M. Bellinzoni, F. Meneghetti
Towards the Inhibition of Protein–Protein Interactions (PPIs) in STAT3: Insights into a New Class of Benzothiadiazole Derivatives
2020 M. Mori, E. Gilardoni, L. Regazzoni, A. Pedretti, D. Colombo, G. Parkinson, A. Asai, F. Meneghetti, S. Villa, A. Gelain
Identification of the mechanism of action of 5,6-dimethyl-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide as STAT3 inhibitor
2020 E. Gilardoni, M. Mori, S. Villa, A. Gelain, L.G. Regazzoni
Synthesis, Characterization, and Biological Evaluation of New Derivatives Targeting MbtI as Antitubercular Agents
2021 M. Mori, G. Stelitano, L.R. Chiarelli, G. Cazzaniga, A. Gelain, D. Barlocco, E.R.E. Pini, F. Meneghetti, S. Villa
Functionalized nanoparticles as potential antibiofilm agents
2021 A. Gelain, M. Mori, F. Meneghetti, P. Molino, P. Hayes, S. Villa
Benzothiadiazole derivatives endowed with STAT3 inhibition
2021 A. Gelain, M. Mori, E. Gilardoni, L. Regazzoni, A. Pedretti, D. Colombo, G. Parkinson, A. Asai, F. Meneghetti, S. Villa
Structural insights into the inhibition of M. tuberculosis salicylate synthase (MbtI)
2021 M. Mori, S. Villa, L.R. Chiarelli, G. Stelitano, A. Gelain, T. Tuccinardi, M. Bellinzoni, F. Meneghetti
Unraveling the interaction mechanism of a benzothiadiazole-2.2-dioxide derivative with STAT3 : towards novel direct inhibitors
2021 M. Mori, E. Gilardoni, L. Regazzoni, A. Pedretti, D. Colombo, G. Parkinson, A. Asai, G. Cazzaniga, F. Meneghetti, S. Villa, A. Gelain
Natural products against key Mycobacterium tuberculosis enzymatic targets : Emerging opportunities for drug discovery
2021 G. Cazzaniga, M. Mori, L. Roberto Chiarelli, A. Gelain, F. Meneghetti, S. Villa
New Nanoparticles Endowed with Antibiofilm Activity
2021 A. Gelain, P. Molino, P. Hayes, S. Villa
Insights on the Modulation of SIRT5 Activity: A Challenging Balance
2022 M. Mori, G. Cazzaniga, F. Meneghetti, S. Villa, A. Gelain
Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections
2022 M. Mori, G. Stelitano, A. Griego, L.R. Chiarelli, G. Cazzaniga, A. Gelain, E. Pini, M. Camera, P. Canzano, A. Fumagalli, E. Scarpa, C. Cordiglieri, L. Rizzello, S. Villa, F. Meneghetti
New strategies to overcome biofilm formation by natural product derivatives
2022 S. Villa, G. Cazzaniga, M. Mori, P.J. Molino, P. Hayes, F. Villa, C. Cattò, F. Cappitelli, A. Gelain
Targeting the mycobactin biosynthesis pathway in M. tuberculosis: a step towards the improvement of the anti-virulence activity of MbtI inhibitors
2022 M. Mori, S. Villa, L.R. Chiarelli, G. Stelitano, A. Gelain, G. Cazzaniga, M. Bellinzoni, L. Rizzello, E. Scarpa, A. Griego, A. Fumagalli, F. Meneghetti
Natural compounds targeting E. Coli WRBA as antibiofilm agents: Virtual screening, design and synthesis of analogs, biological evaluation
2022 S. Villa, M. Mori, I.A. Ratt, F. Meneghetti, G. Roda, A. Gelain, F. Villa, E. Fassi, F. Forlani, G. Grazioso
Development of a novel approach to overcome biofilm formation by natural product derivatives
2022 A. Gelain, G. Cazzaniga, M. Mori, P.J. Molino, P. Hajes, F. Villa, C. Cattò, F. Cappitelli, S. Villa
Targeting Siderophore-Mediated Iron Uptake in M. abscessus: A New Strategy to Limit the Virulence of Non-Tuberculous Mycobacteria
2023 M. Mori, G. Stelitano, G. Cazzaniga, A. Gelain, A. Tresoldi, M. Cocorullo, M. Roversi, L.R. Chiarelli, M. Tomaiuolo, P. Delre, G. Felice Mangiatordi, A. Griego, L. Rizzello, A. Cassetta, S. Covaceuszach, S. Villa, F. Meneghetti
Natural and nature-inspired compounds targeting E. coli WrbA as antibiofilm agents: computational studies, synthesis, and biological evaluation
2023 M. Mori, S. Villa, A. Ratti, F. Meneghetti, G. Roda, A. Gelain, F. Villa, E.M.A. Fassi, F. Forlani, G. Grazioso
Optimizing the drug discovery process for the development of MbtI inhibitors as promising anti-virulence agents against TB
2023 M. Mori, G. Cazzaniga, A. Tresoldi, A. Gelain, L.R. Chiarelli, G. Stelitano, M. Bellinzoni, S. Villa, F. Meneghetti
Discovery of novel SIRT5 activators as potential anti-inflammatory agents
2023 A. Gelain, . Mori, G. Cazzaniga, F. Meneghetti, . Wong, L. Jun Yan, P.S. Coghi, S. Villa
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile